Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
424.00    -15.00 (-3.42%)
Bid:
426.00
Ask:
430.00
Spread: 4.00 (0.939%)
Market Cap: £208.53m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Third Quarter Trading Update

1 Nov 2017 07:00

RNS Number : 1767V
Zotefoams PLC
01 November 2017
 

Zotefoams plc

("Zotefoams" or the "Company" or "Group")

 

Trading Update

 

1st November 2017 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the third quarter ended 30 September 2017.

 

Zotefoams is pleased to report continued strong trading during the third quarter, maintaining the momentum of organic sales growth experienced in the first half of the year.

 

· Full year revenues expected to be ahead of market expectations

 

· Adjusted profit before tax and exceptional items for the year ending 31 December 2017 expected to be at the top end of the range of market expectations

 

· Group revenue 22% ahead for the third quarter against the comparative period

 

· Group revenue 24% ahead for the first nine months against the comparative period

 

In constant currency sales grew 16% in the third quarter following a 14% increase for the first six months of the year. The year-to-date growth has been delivered across all business units, with particularly strong growth in High-Performance Products, during the third quarter.

 

Management continues to invest in its strong portfolio of growth prospects and to manage the higher growth rates of early stage opportunities. The order book for the fourth quarter gives confidence that the Company will exceed market expectations for Group revenue and therefore, at current foreign exchange rates, the Board expects adjusted profit before tax and exceptional items for the year ending 31 December 2017 to be at the top end of the range of market expectations.

 

 

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"We are delighted with the strong organic growth achieved across all business units during the third quarter of 2017. Our ambition is to establish ourselves as the world leader in cellular materials technology in our chosen markets. To achieve this ambition, we are investing significantly in new equipment and enhanced business capability. The Board is confident of another year of positive progress and about the long-term prospects for the business."

 

 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory

+44 (0) 203 053 8671

Graham Herring

Miles Nolan

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces and sells lightweight AZOTE® polyolefin and ZOTEK® high-performance foams for diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®).

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUARWRBBAROAA
Date   Source Headline
6th Jun 20238:00 amRNSNike Exclusivity Agreement Extension
24th May 202311:40 amRNSResult of the 2023 Annual General Meeting
24th May 20237:00 amRNSTrading Update and Chair Succession
12th May 202310:42 amRNSNotification Of Transactions Of Directors/PDMRs
27th Apr 20237:00 amRNSHigh-performance foam in medical facility doors
26th Apr 20235:44 pmRNSNotification Of Transactions Of Directors/PDMRs
26th Apr 20233:39 pmRNSNotification Of Transactions Of Directors/PDMRs
24th Apr 20235:50 pmRNSReplacement Notice Transactions Of Directors/PDMRs
24th Apr 20234:42 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Apr 20237:00 amRNS2022 Annual Report and Notice of the 2023 AGM
19th Apr 20234:41 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Apr 20231:18 pmRNSNotification Of Transactions Of Directors/PDMRs
27th Mar 20234:35 pmRNSPrice Monitoring Extension
22nd Mar 20231:30 pmRNSHolding(s) in Company
21st Mar 20234:10 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Mar 20234:09 pmRNSHolding(s) in Company
21st Mar 20237:00 amRNSPreliminary Results
14th Mar 20234:58 pmRNSHolding(s) in Company
14th Mar 20233:09 pmRNSNotification Of Transactions Of Directors/PDMRs
28th Feb 20237:00 amRNSAward of AA ESG Ratings assessment
15th Feb 20237:00 amRNSNotice of Results
14th Feb 20233:34 pmRNSNotification Of Transactions Of Directors/PDMRs
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20237:00 amRNSFull Year Trading Update
17th Jan 20237:00 amRNSChair Succession
12th Jan 202311:18 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20227:00 amRNSTrading Update
13th Dec 20224:03 pmRNSNotification Of Transactions Of Directors/PDMRs
6th Dec 20229:42 amRNSNotification Of Transactions Of Directors/PDMRs
5th Dec 202211:34 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 202211:27 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 20227:00 amRNSAppointment of Joint Broker
9th Nov 20227:00 amRNSAcquisition of the assets and IP of Refour ApS
17th Oct 202211:31 amRNSNotification Of Transactions Of Directors/PDMRs
13th Oct 20227:00 amRNSTrading Update
12th Oct 20224:02 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Oct 20224:41 pmRNSSecond Price Monitoring Extn
11th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Sep 20227:00 amRNSIndependent Life Cycle Assessment of ReZorce
13th Sep 20223:43 pmRNSDirector/PDMR Shareholding
23rd Aug 20224:35 pmRNSPrice Monitoring Extension
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
12th Aug 20221:43 pmRNSDirector/PDMR Shareholding
11th Aug 20223:50 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSInterim Results
2nd Aug 20224:35 pmRNSPrice Monitoring Extension
20th Jul 20224:42 pmRNSSecond Price Monitoring Extn
20th Jul 20224:36 pmRNSPrice Monitoring Extension
12th Jul 202212:39 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.